Subconjunctival Bevacizumab injection on primary pterygium in Thammasat University Hospital: a randomized controlled trial
##plugins.themes.bootstrap3.article.sidebar##
##plugins.themes.bootstrap3.article.main##
摘要
Purpose: To evaluate the reduction in horizontal dimension of primary pterygium after subconjunctival Bevacizumab injection.
Materials and methods: Subjects with primary pterygium were randomized to study group (subconjunctival Bevacizumab injection group) and control group. The inclusion criteria were adults (age older than 18) with primary pterygium less than 3 millimeters in horizontal dimension. The primary outcome is the reduction of horizontal dimension at 1 week, 1 month, 3 months and 6 months.
Results: Fifty-nine subjects with primary pterygium were enrolled in this study. The mean age is 56.25 years (± 12.90). Forty-seven subjects were female, the remaining were male. Mean size reduction in the Bevacizumab group was 0.517 mm. (±0.301), 0.710 mm. (±0.359), and 0.790 mm. (±0.361) at 1 month, 3 months and 6 months respectively. Mean size reduction in control group was -0.067 mm. (±0.258), -0.010 mm. (±0.304) and -0.003 mm. (±0.366) at 1 month, 3 months, and 6 months respectively. The p-value of difference in pterygium size reduction between Bevacizumab group and control group is less than 0.001 at all visit.
Conclusion: The reduction of horizontal dimension in primary pterygium at 1 month, 3 months and 6 months is significantly greater in those who received subconjunctival bevacizumab injection compared to the control group.
##plugins.themes.bootstrap3.article.details##
参考
2. Mak RK, Chan TC, Marcet MM, Choy BN, Shum JW, Shih KC, Wong IY, Ng AL. Use of anti-vascular endothelial growth factor in the management of pterygium. Acta Ophthalmol. 2017;95:20-7.
3. Mauro J, Foster CS. Pterygia: pathogenesis and the role of subconjunctival bevacizumab in treatment. Semin Ophthalmol. 2009;24:130-4.
4. Singh P, Sarkar L, Sethi HS, Gupta VS. A randomized controlled prospective study to assess the role of subconjunctival bevacizumab in primary pterygium surgery in Indian patients. Indian J Ophthalmol. 2015;63:779-84.
5. Fallah Tafti MR, Khosravifard K, Mohammadpour M, Hashemian MN, Kiarudi MY. Efficacy of intralesional bevacizumab injection in decreasing pterygium size. Cornea.2011;30:127-9.
6. Pasqualetti G, Danesi R, Del Tacca M, Bocci G. Vascular endothelial growth factor pharmacogenetics: a new perspective for anti-angiogenic therapy. Pharmacogenomics. 2007;8:49-66.
7. Bhisitkul RB. Vascular endothelial growth factor biology: clinical implications for ocular treatments. Br J Ophthalmol. 2006;90:1542-7.
8. Kasetsuwan N, Reinprayoon U, Satitpitakul V. Prevention of Recurrent Pterygium with Topical Bevacizumab 0.05% Eye Drops: A Randomized Controlled Trial. Elsevier HS Journals. 2015;37:10:2347-51.
9. Enkvetchakul O, Thanathanee O, Rangsin R, Lekhanont K, Suwan-apichon O. A randomized controlled trial of intralesional bevacizumab injection on primary pterygium: preliminary results. Cornea 2011;30:1213-8.
10. Razeghinejad MR, Hosseini H, Ahmadi F, Rahat F, Eghbal H. Preliminary results of subconjunctival bevacizumab in primary pterygium excision. Ophthalmic Res. 2010;43:134-8.
11. Shenasi A, Mousavi F, Shoa-Ahari S, Rahimi-Ardabili B, Fouladi RF. Subconjunctival bevacizumab immediately after excision of primary pterygium: the first clinical trial. Cornea. 2011;30:1219-22.
12. Besharati MR, Manaviat MR, Souzani A. Subconjunctival bevacizumab injection in treatment of pterygium. Acta Med Iran. 2011;49:179-83.
13. Mandalos A, Tsakpinis D, Karayannopoulou G, Tsinopoulos I, Karkavelas G, Chalvatzis N, Dimitrakos S.The effect of subconjunctival ranibizumab on primary pterygium: a pilot study.
Cornea. 2010;29:1373-9.
14. Mansour AM. Regression of Inflamed Pterygia by Frequent High-Dose Intralesional Ziv-Aflibercept. Cornea. 2017;36:1002-5.
